Re-expression of the paralogous γ-globin genes (HBG1/2) could be a universal strategy to ameliorate the severe β-globin disorders sickle cell disease (SCD) and β-thalassemia by induction of fetal hemoglobin (HbF, α 2 γ 2 ) 1 . Previously, we and others have shown that core sequences at the BCL11A erythroid enhancer are required for repression of HbF in adultstage erythroid cells but are dispensable in non-erythroid cells 2-6 . CRISPR-Cas9-mediated gene modification has demonstrated variable efficiency, specificity, and persistence in hematopoietic stem cells (HSCs). Here, we demonstrate that Cas9:sgRNA ribonucleoprotein (RNP)-mediated cleavage within a GATA1 binding site at the +58 BCL11A erythroid enhancer results in highly penetrant disruption of this motif, reduction of BCL11A expression, and induction of fetal γ-globin. We optimize conditions for selection-free on-target editing in patient-derived HSCs as a nearly complete reaction lacking detectable genotoxicity or deleterious impact on stem cell function. HSCs preferentially undergo non-homologous compared with microhomology-mediated end joining repair. Erythroid progeny of edited engrafting SCD HSCs express therapeutic levels of HbF and resist sickling, while those from patients with β-thalassemia show restored globin chain balance. Non-homologous end joining repair-based BCL11A enhancer editing approaching complete allelic disruption in HSCs is a practicable therapeutic strategy to produce durable HbF induction.
1
. Previously, we and others have shown that core sequences at the BCL11A erythroid enhancer are required for repression of HbF in adultstage erythroid cells but are dispensable in non-erythroid cells [2] [3] [4] [5] [6] . CRISPR-Cas9-mediated gene modification has demonstrated variable efficiency, specificity, and persistence in hematopoietic stem cells (HSCs). Here, we demonstrate that Cas9:sgRNA ribonucleoprotein (RNP)-mediated cleavage within a GATA1 binding site at the +58 BCL11A erythroid enhancer results in highly penetrant disruption of this motif, reduction of BCL11A expression, and induction of fetal γ-globin. We optimize conditions for selection-free on-target editing in patient-derived HSCs as a nearly complete reaction lacking detectable genotoxicity or deleterious impact on stem cell function. HSCs preferentially undergo non-homologous compared with microhomology-mediated end joining repair. Erythroid progeny of edited engrafting SCD HSCs express therapeutic levels of HbF and resist sickling, while those from patients with β-thalassemia show restored globin chain balance. Non-homologous end joining repair-based BCL11A enhancer editing approaching complete allelic disruption in HSCs is a practicable therapeutic strategy to produce durable HbF induction.
Electroporation of Cas9 and single guide RNA (sgRNA) RNP complexes enables delivery of a transient pulse of genome editing material to human cells 7, 8 . Previously, we had employed lentiviralpooled sgRNA screening to identify a set of sgRNAs targeting the core of the +58 erythroid enhancer of BCL11A, resulting in potent HbF derepression 3 . We used in vitro transcription to produce sgRNAs targeting the BCL11A enhancer and electroporated RNP complexes to healthy donor CD34 + hematopoietic stem and progenitor cells (HSPCs), which resulted in variable editing (9.5-87.0% indels; Extended Data Fig. 1a ,b). Consistent with prior observations, chemically modified synthetic sgRNAs (MS-sgRNAs) produced more efficient editing than in vitro transcribed sgRNAs following RNP electroporation of CD34 + HSPCs 9 . We observed a dose-dependent relationship between RNP concentration and indel frequency and similar editing efficiency at Cas9:sgRNA molar ratios ranging from 1:1 to 1:2.5 (Extended Data Fig. 1c-e) .
Of eight MS-sgRNAs targeting the core of the +58 erythroid enhancer of BCL11A in CD34 + HSPCs, editing efficiency ranged from 66.1-90.7% indel frequency (Fig. 1a,b and Extended Data Fig. 2 ). Editing with sgRNA-1617, which cleaves directly within a GATA1 binding motif 10 at the core of the +58 enhancer, gave the highest levels of γ-globin and HbF induction in erythroid progeny (Fig. 1a,c and Extended Data Fig. 1f,h ). Editing of the BCL11A enhancer resulted in reduction in BCL11A transcript expression by 54.6% (Extended Data Fig. 1j ). We observed a strong correlation between reduction of BCL11A expression and induction of γ-globin and HbF ( Fig. 1d and Extended Data Fig. 1j-l) . Deep sequencing confirmed the high rate of indels, and showed that the most common mutations were +1 base pair (bp) insertions, as produced by imprecise non-homologous end joining repair (NHEJ), followed by −15 bp and −13 bp deletions, each products of microhomologymediated end joining (MMEJ) repair ( Fig. 1f and Extended Data Figs. 1g and 2). We conducted clonal analysis of the erythroid progeny of CD34
+ HSPCs edited at the BCL11A enhancer by sgRNA-1617, assessing genotype, globin gene expression by quantitative PCR with reverse transcription (RT-qPCR), and HbF analysis by HPLC (Extended Data Figs. 1i and 3d,e and Supplementary Table 1 ). Colonies with biallelic enhancer modifications demonstrated elevated γ-globin messenger RNA levels (mean 50.8% of total β-like globin, range 35.3-75.1%, compared with 14.7% in unedited colonies) and elevated HbF protein levels (mean 37.6%, range 27.5-46.9%, compared with 9.1% in unedited colonies). Single base insertions at the sgRNA-1617 cleavage site were just as effective as longer deletions at increasing HbF levels.
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To test if this BCL11A enhancer editing approach would result in clinically meaningful γ-globin induction, we edited CD34 Table 2 ). The RNP editing rate with MS-sgRNA-1617 was similar to that from healthy control HSPCs (mean 84.4% indels; range 75.3-92.5%; Fig. 1e ). RNP editing of the AAVS1 locus served as a functionally neutral control. In each β-thalassemia donor's BCL11A
enhancer edited cells, we demonstrated potent induction of γ-globin (mean 63.6% relative to α-globin; range 33.0-89.0%; Fig. 1f ) and induction of HbF fraction in donors with residual expression of HbA or HbE (Fig. 1g,h ). We hypothesized that therapeutically relevant amelioration of globin chain imbalance, the pathophysiologic underpinning of β-thalassemia, would result in improvement of terminal erythroid maturation. We found a higher frequency of enucleation, larger size, and more circular shape of terminal erythroid cells + HSPCs from patients with β-thalassemia or healthy donors (β A β A ) of indicated β-globin genotypes. f-h, β-like globin expression by RT-qPCR normalized by α-globin (P = 0.00017 for BCL11A enhancer as compared with AAVS1 edited for all comparisons as determined by unpaired two-tailed Student's t-tests), and HbF induction by HPLC analysis in erythroid cells that were in vitro differentiated. i, Enucleation of in vitro differentiated erythroid cells. j, Cell size measured by relative forward scatter intensity. k, Representative microscopy image showing rounder and more uniform appearance of enucleated erythroid cells following BCL11A enhancer editing. Blue arrows indicate poikilocytes. Scale bar, 15 µm. l,m, Imaging flow cytometry was used to establish a circularity index (l) and then to quantify (m) circularity of enucleated erythroid cells. Scale bar, 5 µm. In all graphs, data are plotted as mean ± s.d. and analyzed using unpaired two-tailed Student's t-tests. Data are representative of three biologically independent replicates. Cell size (relative) 
Low circularity (15) High circularity (30) i j k l m 
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in each of the β-thalassemia samples, but no effect on the healthy donor samples, following BCL11A enhancer editing ( Fig. 1i-m) . The durability of an autologous hematopoietic cell therapy depends on the ability to permanently modify stem cells. To test the impact of BCL11A enhancer editing on HSCs, we engrafted edited human CD34 + HSPCs into immunodeficient NBSGW mice, since they support not only myeloid and lymphoid, but also erythroid engraftment 11 . Using two separate donors, we found that the recipients of edited and unedited CD34
+ HSPCs had similar levels of human lymphoid, myeloid, and erythroid cell engraftment within the bone marrow after 16 weeks (Extended Data Fig. 3a,c,d and Supplementary Table 3) . We observed variability in the fraction of indels in the engrafting cells from edited mice, ranging from 13.8 to 85.5% (Extended Data Fig. 3b ).
Comparing the indel frequencies in the input cells with the engrafting cells we observed a mean reduction of 40.9%. In the engrafting bone marrow cells, we found no reduction in BCL11A transcript levels in edited B lymphocytes, but 80.0% reduction in edited erythroid cells, consistent with the strict lineage specificity of these enhancer sequences (Extended Data Fig. 3e,f) . In human erythroid cells from the bone marrow, we observed robust induction of γ-globin, increasing from 1.8 to 46.8% after editing (Extended Data Fig. 3g ). Edited bone marrow cells were able to support secondary transplantation to a similar level as unedited cells, while maintaining a mean indel frequency of 72.2%, consistent with gene editing of self-renewing HSCs (Extended Data Fig. 3h,i ). Long-term engrafting HSCs not bearing biallelic therapeutic edits represent a possible barrier to full therapeutic benefit. In SCD a minority fraction of residual sickle erythrocytes can potentially result in negative rheologic and pathologic consequences 12, 13 . Therefore we investigated methods to maximize editing efficiency in HSCs.
The SpCas9 protein we used in the experiments described above included two SV40 nuclear localization sequences (NLSs) on the carboxy (C) terminus 14 (subsequently called 2xNLS-Cas9). We hypothesized that additional orthogonal NLSs could improve genome editing efficiency. We appended a c-Myc-like NLS to the amino (N) terminus and both SV40 and nucleoplasmin NLSs to the C terminus of SpCas9 (subsequently called 3xNLS-Cas9) (Fig. 2a) . We electroporated human CD34
+ HSPCs with BCL11A enhancertargeting RNPs at concentrations ranging from 1 to 10 μM and found increased indel frequencies at all doses with 3xNLS-Cas9 (Fig. 2b) . At doses of 5 μM and greater the indel frequency exceeded 95%. The viability of cells electroporated with 3xNLS-Cas9 was inferior compared with those receiving 2xNLS-Cas9. However, as the concentration of 2xNLS-Cas9 was reduced, viability approached that of 3xNLS-Cas9-treated cells (Fig. 2c) , suggesting that a component of the diluent for 2xNLS-Cas9 might be protective. The 2xNLS-Cas9 stock was dissolved in 10% glycerol, whereas the 3xNLS-Cas9 stock was not dissolved in glycerol. We electroporated cells with 3xNLS-Cas9 with a final glycerol concentration ranging from 0 to 8% and found that additional glycerol protected the cells from loss of viability (Fig. 2d ). This protective effect was observed with 2xNLS-Cas9, 3xNLS-Cas9, and without Cas9, indicating that glycerol was protective against electroporation-mediated toxicity independent of genome editing (Fig. 2d) . We observed similar protection against electroporation toxicity with glycine, consistent with a possible osmoprotectant effect (Extended Data Fig. 4a ). There was a slight decrement of editing with increasing doses of glycerol, suggesting a balance between maximizing cell viability and genome editing efficiency (Fig. 2e) . We found that 3xNLS-Cas9 RNP electroporation was able to achieve up to 98.1% indels in CD34 + HSPCs (Fig. 2f and Extended Data Fig. 4b,c) . There was a similar distribution of alleles as with 2xNLS-Cas9 editing, with the +1 bp insertion the most frequent indel, followed by the −15 bp and −13 bp deletions. We observed a similar magnitude of decrease in BCL11A mRNA and protein level during in vitro erythroid maturation with 2xNLS-Cas9 or 3xNLS-Cas9 RNP electroporation, although there was a modest increase in both γ-globin and HbF induction with 3xNLS-Cas9 (P < 0.05; Fig. 2g and Extended Data Fig. 4d-g ).
We hypothesized that maximizing genome editing efficiency might increase the fraction of indels in engrafting edited HSCs and enhance HbF induction in erythroid progeny. RNP electroporation with 3xNLS-Cas9 and BCL11A enhancer MS-sgRNA-1617 resulted in similar human marrow engraftment after 16 weeks with edited and unedited CD34
+ HSPCs, with a dose-dependent relationship between cell infusion dose and human cell engraftment ( Fig. 2h and Extended Data Fig. 8b ). We observed no difference in human engraftment if cells were infused 0, 1, or 2 d following electroporation (Extended Data Fig. 6a ). Edited cells showed similar capacity for lymphoid, myeloid, and erythroid engraftment ( Fig. 2i and Extended Data Fig. 5b,c) . Engrafting human cells maintained 96.5% indels, similar to the 98.1% indels observed in the input cells ( Fig. 2j and Extended Data Fig. 5d ). In the bone marrow, BCL11A expression was preserved in edited B lymphocytes but reduced by 82.7% in edited erythroid cells (Fig. 2k,l) . γ-Globin was elevated from 2.2% to 70.8% total β-like globin in edited human erythroid cells (Fig. 2m and Extended Data Fig. 5c ). Transplant of CD34
+ HSPCs electroporated with 3xNLS-Cas9 and MS-sgRNA-1617 and supplemented with 2%, 4% or 6% glycerol also yielded potent human engraftment while maintaining high indel frequencies in the repopulating cells (Extended Data Fig. 5e-h ). The 3xNLS-Cas9 edited bone marrow cells were also able to support secondary transplantation to a similar level as unedited cells, while maintaining a mean indel frequency of 96.5%, consistent with gene editing of self-renewing HSCs (Fig. 2n,o and Extended Data Fig. 9d,e) . The high efficiency of therapeutic editing within engrafting hematopoietic cells was consistently observed using HSPCs from four different healthy donors (Fig. 2h-o and Extended Data Fig. 5 ).
To test the specificity of the RNP sgRNA-1617, we performed CIRCLE-seq, a method to define genome-wide target sequences susceptible to RNP cleavage in vitro 15 , identifying 20 potential offtarget sites (Extended Data Fig. 6a and Supplementary Table 4) . Amplicon deep sequencing of each of these 20 off-target sites from CD34 + HSPCs edited with both 2xNLS-Cas9 and 3xNLS-Cas9 did not identify any off-target sites at which we observed Cas9-dependent indels, at the limit of detection of 0.1% allele frequency (Extended Data Fig. 6b ). From the same edited genomic DNA, we observed 81.0-95.5% on-target indels at the BCL11A enhancer. In addition, we tested, by amplicon deep sequencing, four additional in silico predicted off-target sites not identified by CIRCLEseq (Supplementary Table 5 ) and did not detect indels (Extended Data Fig. 6b ). Recent studies have emphasized that p53 is induced following programmable nuclease-mediated DNA cleavage 16, 17 . Consistent with intact DNA damage response, we observed transient induction of P21 transcript following Cas9:sgRNA RNP electroporation to CD34 + HSPCs, with peak levels between 4 and 8 hours after electroporation (Extended Data Fig. 6c ). Since we did not observe a difference in human chimerism in xenotransplant recipients, it appeared unlikely that this DNA damage response had a major impact on HSPC engraftment potential. In pluripotent stem cells, clones with P53 mutation or inhibition have been reported to have a selective advantage following gene editing 17 . We performed targeted deep sequencing of edited CD34 + HSPCs using a clinically approved 95-gene sequencing panel designed to identify recurrent somatically acquired hematologic malignancyassociated mutations, including TP53 among loci tested 18 . We did not observe variant alleles at TP53 or any other of the hematologic malignancy-associated loci in the edited HSPCs (Supplementary Table 6 ). Together, these data indicate an absence of detectable genotoxicity.
To determine whether this optimized BCL11A enhancer editing strategy could be effective in SCD, we obtained plerixafor-mobilized peripheral blood CD34
+ HSPCs from two patients [19] [20] [21] . We Fig. 7e ). In vitro erythroid differentiated progeny showed 47.6% γ-globin in edited cells compared with 4.5% in unedited cells (Fig. 3b) . Clonal analysis demonstrated that biallelic indels of the BCL11A enhancer, as short as 1 bp in length, resulted in robust induction of γ-globin, consistent with healthy donor results (total of 63 colonies analyzed from four donors; Fig. 3c , Supplementary Table 1 , and Extended Data Figs. 1i and 3d,e). We observed similar human lymphoid, myeloid, and erythroid engraftment of edited and unedited SCD HSPCs ( Fig. 3d and Extended Data Fig. 7b,c,g ). There were similar results when edited cells were infused 1 or 2 d following editing (Extended Data Fig. 7a-d ). Edited cells showed 96.7% indels after 16 weeks of bone marrow engraftment compared with 95.0% indels in input HSPCs (Fig. 3e) . BCL11A expression in erythroid cells was reduced by 83.1% while it was preserved in B lymphocytes (Fig. 3f,g ). Edited bone marrow human erythroid cells expressed 59.0% γ-globin compared with 3.5% in unedited cells (Fig. 3h) . The edited bone marrow SCD cells were able to support secondary transplantation to a similar level as unedited SCD cells, while maintaining a mean indel frequency of 98.1%, consistent with gene editing of self-renewing HSCs (Fig. 3i, 
j). CD34
+ HSPCs were collected from the bone marrow of mice engrafted by SCD and healthy donor cells and subject to in vitro erythroid differentiation. Glycerol ( Erythroid cells differentiated in vitro from the bone marrow of mice engrafted with 3xNLS-Cas9 edited cells showed more potent induction of HbF compared with 2xNLS-Cas9 edited cells, consistent with greater persistence of edited alleles in repopulating HSCs (Extended Data Fig. 8a,d ). Comparing all of the transplant results, there was a strong correlation (Spearman r = 0.99, P < 0.0001) between indel frequencies in input HSPCs compared with human cells engrafting the bone marrow after 16 weeks (Fig. 4a) . With reduced RNP concentration, we observed disproportionate loss of indels from an HSC-enriched immunophenotype population compared with bulk HSPCs (Extended Data Fig. 8e ). We found that the indel spectrum in repopulating cells was different from that in γ-Globin (% β-like globin) 
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input HSPCs (Fig. 4b and Extended Data Fig. 9a,b) . For example, in HSPCs edited with 2xNLS-Cas9 with 2% glycerol the second and third most common indels were 15-bp and 13-bp deletions, comprising together 25.9% of alleles (Fig. 4b) . These deletions were nearly absent in the engrafted cells, comprising together 1.0% of alleles. The 15-bp and 13-bp deletions were both predicted products of MMEJ repair 22 (Supplementary Table 7 ). These results suggested that NHEJ may be favored relative to MMEJ repair in the long-term repopulating HSC population relative to the bulk HSPC population. We classified each of the repair alleles, at BCL11A and AAVS1, as originating from NHEJ or MMEJ and compared their abundance in input HSPCs used for transplantation or in the engrafted cells resulting from these transplants. Together these data comprised ten independent transplants conducted with 33 recipient mice across BCL11A and AAVS1. We observed a significant decrease in the fraction of edited alleles repaired by MMEJ (median 25.2% versus 3.4%, P < 0.0001) and a concomitant increase in the fraction of edited alleles repaired by NHEJ (median 64.5% versus 81.0%, P < 0.005) in engrafted human cells compared with input HSPCs (Fig. 4c and Extended Data Fig. 9c ). Since we observed similar results targeting BCL11A and AAVS1, it appeared unlikely there was locus-specific selection against MMEJ-edited repopulating cells. We speculated that quiescent HSCs would be relatively refractory to MMEJ repair, predominantly found in S and G2 phases of the cell cycle 23, 24 .
Comparing CD34
+ HSPCs immediately after thawing and following 24 hours in culture, we observed similar HSC immunophenotype by CD34, CD38, CD90, and CD45RA markers, increase of cell size, and shift from predominantly G0 to active cycling (Extended Data ) or on the basis of G0, G1, S, and G2/M phase gates. Following an additional 4 d in culture, we determined the indel spectrum by sequence analysis. We observed depletion of the MMEJ alleles and enrichment of NHEJ alleles from the HSC compared with committed progenitor population for both BCL11A enhancer and AAVS1 edited cells (Fig. 4d,f and Extended Data Fig. 9f ). We found near-complete absence of MMEJ alleles from G0 and G1 phase HSPCs and enrichment in G2/M phase HSPCs after BCL11A enhancer or AAVS1 editing (Fig. 4e,g and Extended Data Fig. 9g ). These data suggest that quiescent and engrafting HSCs appear to favor NHEJ compared with MMEJ repair [23] [24] [25] . Previous experiments of genome editing in human HSPCs have shown variability in editing efficiency, specificity, and persistence in long-term engrafting HSCs (see Supplementary Table 8) 6, [26] [27] [28] [29] [30] [31] [32] [33] [34] . Most prior studies have shown some reduction in indel frequency in engrafting cells compared with input HSPCs (Supplementary Table 8 ). The durability of therapeutic genome edits in the context of human hematopoietic autotransplant remains uncertain.
Here we address this concern by introducing therapeutic edits as a nearly complete reaction in long-term engrafting HSCs. We developed an optimized protocol for selection-free, HSC expansion-free BCL11A enhancer editing using modified synthetic sgRNA, SpCas9 protein with an additional NLS, and reformulated electroporation buffer in which we achieve ~95% therapeutic edits in healthy donor 
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and patient-derived engrafting cells without detectable genotoxicity. Even 1 bp indels following cleavage at core sequences within the BCL11A erythroid enhancer disrupt the GATA1-binding motif and are sufficient for robust HbF induction. Although we did not specifically investigate on-target large deletions following Cas9 cleavage 35 , we have previously observed kilobase-scale deletions at the intronic BCL11A erythroid enhancer to result in erythroid-restricted loss of BCL11A expression [2] [3] [4] . Alternative plausible strategies for genome editing to ameliorate the β-hemoglobinopathies include targeting the β-globin cluster for gene repair or to mimic hereditary persistence of fetal hemoglobin alleles 26, 27, 30, [36] [37] [38] [39] . The efficiency of these homology-and microhomology-based maneuvers in HSCs in the absence of selection or HSC expansion remains to be determined, and in the case of gene repair the clinically relevant delivery of an extrachromosomal donor sequence presents an additional challenge. Ex vivo BCL11A enhancer editing approaching complete allelic disruption appears to be a realistic and scalable strategy with existing technology for durable HbF induction for the β-hemoglobinopathies. Emulating this efficiency could contribute to the success of industry-sponsored clinical trials of BCL11A enhancer editing using zinc finger nucleases (NCT03432364) and Cas9 (NCT03655678). Highly efficient HSC editing could be adapted for biological investigation and genetic amelioration of additional blood disorders 40 .
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by NHGRI (grant no. R00HG008399). S.A.W. was supported by NIAID (grant no. R01AI117839) and NIGMS (grant no. R01GM115911 + HSPCs were thawed on day 0 into X-VIVO 15 (Lonza, 04-418Q) supplemented with 100 ng ml −1 human stem cell factor (SCF), 100 ng ml −1 human thrombopoietin (TPO), and 100 ng ml −1 recombinant human Flt3-ligand (Flt3-L). HSPCs were electroporated with Cas9 RNP 24 h after thawing and maintained in X-VIVO media with cytokines. For in vitro erythroid maturation experiments, 24 h after electroporation, HSPCs were transferred into erythroid differentiation medium (EDM) consisting of IMDM supplemented with 330 μg ml −1 holo-human transferrin, 10 μg ml −1 recombinant human insulin, 2 IU ml −1 heparin, 5% human solvent detergent pooled plasma AB, 3 IU ml
erythropoietin, 1% l-glutamine, and 1% penicillin/streptomycin. During days 0-7 of culture, EDM was further supplemented with 10 -6 M hydrocortisone (Sigma), 100 ng ml −1 human SCF, and 5 ng ml −1 human IL-3 (R&D) as EDM-1. During days 7-11 of culture, EDM was supplemented with 100 ng ml −1 human SCF only as EDM-2. During days 11-18 of culture, EDM had no additional supplements, as EDM-3. Enucleation percentage and γ-globin induction were assessed on day 18 of erythroid culture.
In vitro transcription of sgRNAs. First, sgRNAs with T7 promoter were amplified by PCR from pX458 plasmid with specific primers (Supplementary Table 9 ) and in vitro transcribed using MEGAshortscript T7 kit (Life Technologies). After transcription, the sgRNAs were purified with MEGAclear kit (Life Technologies) according to manufacturer's instructions.
RNP electroporation. Electroporation was performed using Lonza 4D
Nucleofector (V4XP-3032 for 20 μl Nucleocuvette Strips or V4XP-3024 for 100 μl Nucleocuvettes) as the manufacturer's instructions. 2xNLS-Cas9 was obtained from QB3 MacroLab, University of California, Berkeley. The modified synthetic sgRNA (2′-O-methyl-3′-phosphorothioate modifications in the first and last three nucleotides) was from Synthego. sgRNA concentration was calculated using the full-length product reporting method, which is threefold lower than the optical density reporting method. CD34
+ HSPCs were thawed 24 h before electroporation. For 20 μl Nucleocuvette Strips, the RNP complex was prepared by mixing Cas9 (200 pmol) and sgRNA (200 pmol, full-length product reporting method) and incubating for 15 min at room temperature immediately before electroporation. For indicated experiments in which glycerol was supplemented, 30% glycerol solution was added to Cas9 protein before addition of sgRNA. HSPCs (5 × 10 4 ) resuspended in 20 μl P3 solution were mixed with RNP and transferred to a cuvette for electroporation with program EO-100. For 100 μl cuvette electroporation, the RNP complex was made by mixing 1,000 pmol Cas9 and 1,000 pmol sgRNA. HSPCs (5 M) were resuspended in 100 μl P3 solution for RNP electroporation as described above. The electroporated cells were resuspended with X-VIVO media with cytokines and changed into EDM 24 h later for in vitro differentiation. For mouse transplantation experiments, cells were maintained in X-VIVO 15 with SCF, TPO, and Flt3-L for 0-2 d as indicated before infusion.
Measurement of cell viability and indel frequencies.
For the viability analysis, cell numbers were counted 48 h after electroporation, the viability was calculated as the cell number ratio of electroporated cells to mock control without electroporation. Indel frequencies were measured with cells cultured in EDM 5 d after electroporation. Briefly, genomic DNA was extracted using the Qiagen Blood and Tissue kit. BCL11A enhancer DHS +58 functional core was amplified with KOD Hot Start DNA polymerase and corresponding primers (Supplementary Table 9 ) using the following cycling conditions: 95 °C for 3 min; 35 cycles of 95 °C for 20 s, 60 °C for 10 s, and 70 °C for 10 s; 70 °C for 5 min. Resulting PCR products were subjected to Sanger sequencing. Sequencing traces were imported to TIDE software for indel frequency measurement with 40 bp decomposition window.
RT-qPCR quantification of γ-globin induction and p21 expression. RNA isolation with RNeasy columns (Qiagen, 74106), reverse transcription with iScript cDNA synthesis kit (Bio-Rad, 170-8890), and RT-qPCR with iQ SYBR Green Supermix (Bio-Rad, 170-8880) was performed to determine γ-globin induction using primers amplifying HBG1/2, HBB, or HBA1/2 cDNA (Supplementary Table 9 ). For quantification of p21 mRNA, HSPCs were electroporated 24 h postthawing, then were cultured in X-VIVO 15 medium plus cytokines as described above and collected at different time points post-editing. Determination of BCL11A mRNA and protein level. Cells were directly lysed into the RLT plus buffer (Qiagen) for total RNA extraction according to manufacturer's instructions provided in the RNeasy Plus Mini Kit. BCL11A mRNA expression was determined by primers amplifying BCL11A or CAT as internal control (Supplementary Table 9 ). We used CAT as a reference transcript since it is both highly expressed and stable throughout erythroid maturation 41 . All gene expression data represent the mean of at least three technical replicates. For in vitro differentiation, BCL11A mRNA level was measured on day 11 unless otherwise indicated. BCL11A protein level was measured by western blot analysis as described previously 42 with the following antibodies: BCL11A (Abcam, ab19487), GAPDH (Cell Signaling, 5174s). The western blot results were quantified with ImageJ software.
Clonal culture of CD34
+ HSPCs. Edited CD34 + HSPCs were sorted into 150 μl EDM-1 in 96-well round-bottom plates (Nunc) at one cell per well using FACSAria II. The cells were changed into EDM-2 media 7 d later in 96-well flat-bottom plates (Nunc). After an additional 4 d of culture, 1/10 of cells in each well were collected for genotyping analysis, the remaining cells were changed into 150-500 μl EDM-3 at 1 M ml −1 for further differentiation. After an additional 7 d of culture, 1/10 of the cells were stained with Hoechst 33342 for enucleation analysis, the remaining cells were collected with sufficient material for RNA isolation with RNeasy Micro Kit (74004, Qiagen) and RT-qPCR in technical triplicate or a single hemoglobin HPLC measurement per colony.
In vitro sickling and microscopy analysis. In vitro differentiated erythroid cells were stained with 2 μg ml −1 of the cell-permeable DNA dye Hoechst 33342 (Life Technologies) and the enucleated cells which are negative for Hoechst 33342 were FACS sorted and subjected to in vitro sickling assay. Sickling was induced by adding 500 μl freshly prepared 2% sodium MBS solution prepared in PBS into enucleated cells resuspended with 500 μl EDM-3 in a 24-well plate, followed by incubation at room temperature. Live cell images were acquired using a Nikon Eclipse Ti inverted microscope. Image acquisition was performed at room temperature and air in a 24-well plate. Time lapse images were recorded for 30 min with 10 s of intervals per sample.
Human CD34
+ HSPC transplant and flow cytometry analysis. All animal experiments were approved by the Boston Children's Hospital Institutional Animal Care and Use Committee. + HSPCs was detected by flow cytometry as described previously 43 . Cells were resuspended in pre-warmed HSPC medium. First, we added Hoechst 33342 to a final concentration of 10 μg ml −1 and incubated at 37 °C for 15 min. Then we added Pyronin Y directly to cells at a final concentration of 3 μg ml −1 and incubated at 37 °C for 15 min. After washing with PBS, we performed flow cytometric analysis or cell sorting. Cell sorting was performed on a FACSAria II machine (BD Biosciences).
Amplicon deep sequencing. For indel frequencies or off-target analysis with deep sequencing, BCL11A enhancer loci or potential off-target loci were amplified with corresponding primers first (Supplementary Table 9 ). After another round of PCR with primers containing sample-specific barcodes and adapter, amplicons were sequenced for 2 × 150 paired-end reads with MiSeq Sequencing System (Illumina). The deep sequencing data were analyzed by CRISPResso software 44 . In particular, we used a minimum alignment identity of 75%, window size of 2 bp around the cleavage site to quantify indels, an average PHRED quality score of 30, and excluded substitutions to limit potential false-positives. For OT10, in which the amplicon includes homologous genomic sequences, we used a minimum alignment identity of 90%.
Flow cytometry for F-cell, enucleation, and cell size analysis. Intracellular staining was performed as described previously. Cells were fixed with 0.05% glutaraldehyde (Sigma) for 10 min at room temperature and then permeabilized with 0.1% Triton X-100 (Life Technologies) for 5 min at room temperature. Cells were stained with anti-human antibodies for HbF (clone HbF-1 with FITC; Life Technologies) for 30 min in the dark. Cells were washed to remove unbound antibody before FACS analysis. Control cells without staining were used as negative control. For the enucleation analysis, cells were stained with 2 μg ml −1 of the cell-permeable DNA dye Hoechst 33342 (Life Technologies) for 10 min at 37 °C. The Hoechst 33342-negative cells were further gated for cell size analysis with Forward Scatter (FSC) A parameter. Median value of forward scatter intensity normalized by data from healthy donors collected at the same time was used to characterize the cell size.
Imaging flow cytometry analysis. In vitro differentiated D18 erythroid cells stained with Hoechst 33342 were resuspended with 150 μl DPBS for analysis with Imagestream X Mark II (Merck Millipore). Well-focused Hoechst-negative single cells were gated for circularity analysis with IDEAS software. Cells with circularity score above 15 were further gated to exclude cell debris and aggregates. No fewer than 2,000 gated cells were analyzed to obtain a median circularity score.
Preparation of 3xNLS-SpCas9. The plasmid expressing 3xNLS-SpCas9 was constructed in the pET21a expression plasmid (Novagen) and is available on Addgene (ID #114365). The recombinant Streptococcus pyogenes Cas9 with a 6xHis tag and c-Myc-like NLS at the N terminus 45 , SV40, and nucleoplasmin NLS at the C terminus was expressed in Escherichia coli Rosetta (DE3)pLysS cells (EMD Millipore). Cells were grown at 37 °C to an OD 600 of ~0.2, then shifted to 18 °C and induced at an OD 600 of ~0.4 for 16 h with IPTG (1 mM final concentration). Following induction, cells were resuspended with Nickel-NTA buffer (20 mM Tris, 500 mM NaCl, 20 mM imidazole, 1 mM TCEP, pH 8.0) supplemented with HALT protease inhibitor and lysed with M-110s Microfluidizer (Microfluidics) following the manufacturer's instructions. The protein was purified with Ni-NTA resin and eluted with elution buffer (20 mM Tris, 250 mM NaCl, 250 mM imidazole, 10% glycerol, pH 8.0). Subsequently, 3xNLS-SpCas9 protein was further purified by cation exchange chromatography (column, 5 ml HiTrap-S; buffer A, 20 mM HEPES pH 7.5, 1 mM TCEP; buffer B, 20 mM HEPES pH 7.5, 1 M NaCl, 1 mM TCEP; flow rate, 5 ml min −1; column volume, 5 ml) and size-exclusion chromatography on Hiload 16/600 Superdex 200 pg column (isocratic size-exclusion running buffer: 20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM TCEP), then reconstituted in a formulation of 20 mM HEPES and 150 mM NaCl, pH 7.4. CIRCLE-seq library preparation and data analysis. CIRCLE-seq experiments were performed as described previously 15 . In brief, purified genomic DNA was sheared to an average length of 300 bp, end repaired, A tailed, and ligated to uracil-containing stem-loop adapter. Adapter-ligated DNA was treated with Lambda Exonuclease (NEB) and E. coli Exonuclease I (NEB), followed by treatment with USER enzyme (NEB) and T4 polynucleotide kinase (NEB), then circularized with T4 DNA ligase, and treated with Plasmid-Safe ATP-dependent DNase (Epicentre) to degrade linear DNA. The circularized DNA was in vitro-cleaved by SpCas9 RNP coupled with sgRNA-1617. Cleaved products were A tailed, ligated with a hairpin adapter, treated with USER enzyme (NEB), and amplified by Kapa HiFi polymerase (Kapa Biosystems). The libraries were sequenced with 150 bp paired-end reads on an Illumina MiSeq instrument. The CIRCLE-seq sequencing data were analyzed by open-source Python package circleseq (https://github.com/tsailabSJ/circleseq).
Microhomology analysis.
The sequence around the sgRNA-1617 target site of BCL11A enhancer region was uploaded to Microhomology-Predictor of CRISPR RGEN tools (http://www.rgenome.net/mich-calculator/) for microhomology sequence analysis. The 13-bp and 15-bp deletions have corresponding pattern scores of 283.2 and 261.0, respectively. The corresponding indel patterns were also identified by deep sequencing analysis. For BCL11A enhancer and AAVS1, indel sizes from −9 to −20 bp (representing most of the RGEN-predicted microhomology indels) were classified as MMEJ repaired alleles and indel sizes from −8 to +6 were classified as NHEJ repaired alleles.
Statistics and reproducibility. We utilized unpaired two-tailed Student's t-test,
Pearson correlation, and Spearman correlation using GraphPad Prism, for analyses, as indicated in the figure legends. + CD38 − CD90 + CD45RA − sorted population compared with bulk pre-sorted HSPCs after editing by 2 µM or 5 µM RNP. All data represent the mean ± s.d. Statistically significant differences are indicated as follows: ****P < 0.0001, **P < 0.01 (P = 0.0046) as determined by unpaired t-test. f, Comparison of β-like globin expression by RT-qPCR between erythroid cells in vitro differentiated from RNP edited CD34 + HSPCs (pre-engraftment) and engrafted bone marrow (post-engraftment). Statistically significant differences are indicated as follows: ****P < 0.0001, ***P < 0.001 (P = 0.0006), **P < 0.01 (P = 0.0092) as determined by unpaired t-test. In all panels, data are plotted as mean ± s.d. and analyzed using unpaired two-tailed Student's t-tests. Data are from indicated number of mice for a,b,d or representative of three biologically independent replicates for c,e,f. 
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Sample size
At least three mice used per donor for xenotransplant.
Data exclusions No data were excluded from the analyses.
Replication
All the experiments are replicated more than three times.
Randomization Not relevant. All recipient mice were female, 4-5 weeks of age.
Blinding
Not relevant for objective measures.
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Antibodies
Antibodies used
All antibodies used in this study were described in the manuscript and available from standard commercial sources.
Validation
Each antibody for the species and application is validated.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals NOD.Cg-KitW-41J Tyr + Prkdcscid Il2rgtm1Wjl (NBSGW) female mice (4-5 weeks of age) were obtained from Jackson Laboratory (Stock 026622).
Wild animals
The study did not involve wild animals.
Field-collected samples
The study did not involve samples collected from the field.
